MoonLake Immunotherapeutics
MLTX
42 hedge funds and large institutions have $109M invested in MoonLake Immunotherapeutics in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
2.02% less ownership
Funds ownership: 91.44% → 89.42% (-2%)
9% less funds holding
Funds holding: 46 → 42 (-4)
11% less capital invested
Capital invested by funds: $122M → $109M (-$13.5M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$2.8M |
| 2 |
HM
HealthCor Management
New York
|
+$662K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$276K |
| 4 |
MWM
Meridian Wealth Management
Lexington,
Kentucky
|
+$208K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.91M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$1.82M |
| 3 |
Janus Henderson Group
London,
|
-$1.12M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$796K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$565K |
MLTX Hedge Fund Activity: Q1 2021 in Review
42 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2021, worth a combined $109M — down 11% from $122M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MLTX and 4 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was STALEY CAPITAL ADVISERS, adding an estimated $2.8M. The largest seller was Wellington Management Group, cutting an estimated $1.91M.
- 42 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2021, down from 46 in Q4 2020.
- Funds reported $109M of MoonLake Immunotherapeutics stock for Q1 2021, down 11% quarter-over-quarter.
- 4 funds opened new MoonLake Immunotherapeutics positions in Q1 2021 and 8 closed out, a net change of -4 holders.
- The largest MoonLake Immunotherapeutics buyer in Q1 2021 was STALEY CAPITAL ADVISERS, an estimated $2.8M added.
- The largest MoonLake Immunotherapeutics seller in Q1 2021 was Wellington Management Group, an estimated $1.91M sold.
Based on aggregated 13F filings for Q1 2021.